Adrenocortical Hormones API Market Size is valued at USD 2.24 Bn in 2023 and is predicted to reach USD 3.55 Bn by the year 2031 at a 6.04% CAGR during the forecast period for 2024-2031.
Adrenocortical hormones, also referred to as corticosteroids or adrenal cortex hormones, are steroid hormones synthesized by the adrenal cortex, which is a component of the adrenal gland. This hormone is synthesized or extracted to be used as API (Active Pharmaceutical Ingredients) in medications that are designed to treat a variety of conditions related to inflammation, immune response, and metabolism. Adrenocortical hormones, when used as API, play a crucial role in the field of pharmaceuticals. They provide essential treatments for a variety of disorders that impact millions of people globally. Ongoing research and regulation are focused on developing and producing them while ensuring a balance between effectiveness and safety.
Adrenocortical hormone-active pharmaceutical ingredients are in high demand in the pharmaceutical industry because of the rising incidence of hormonal imbalances brought about by increased public knowledge of the problem and better diagnostic tools. The market demand for this adrenocortical hormones API is being driven by In addition, the demand for adrenocortical hormones is on the rise due to the fact that more people are able to access treatment alternatives due to rising healthcare spending and healthcare infrastructure expansion around the world. The demand for adrenocortical hormones API is being driven by the growing number of people who can afford healthcare services, which is a consequence of the healthcare industry’s expansion.
However, market growth is impeded by a stringent regulatory landscape and high costs. The COVID-19 pandemic brought up many issues for healthcare manufacturers, such as shaky marketplaces, falling consumer trust, and messed-up import/export processes. In addition, the adrenocortical hormones API market is being significantly influenced by research in pharmaceutical production and technical improvements; manufacturers and researchers are putting money into state-of-the-art technology and new methods, providing opportunities for market growth in the coming years.
Competitive Landscape
Some Major Key Players In The Adrenocortical Hormones API Market:
- Sanofi (France)
- GlaxoSmithKline (U.K.)
- Xianju Pharma (China)
- Teva (Israel)
- Piramal Pharma Solutions
- Guangzhou Tosun Pharmaceutical
- BCN Peptides
- Guangdong VTR Bio-Tech Co., Ltd,
- Symbiotec Pharmalab,
- Sun Pharmaceutical,
- Cipla,
- Hovione,
- Shandong Xinhua Pharmaceutical Company Limited,
- Steroid SpA,
- Junye Pharmaceutical Co., Ltd.,
- Avik Pharmaceutical,
- Tianjin Pacific Pharmaceutical Co., Ltd (TJPP)
- Shandong Sito Bio-technology CO., LTD.
- Other Market Players
Market Segmentation:
The adrenocortical hormones API market is segmented based on type and application. Based on type, the market is segmented into dexamethasone series, betamethasone series, hydrocortisone series, and others. By application, the market is segmented into injectable drugs, oral drugs, external use drugs, and inhalation drugs.
Based On The Type, The Hydrocortisone Series Adrenocortical Hormones API Segment Is Accounted As A Major Contributor To The Adrenocortical Hormones API Market.
The hydrocortisone series adrenocortical hormones API adrenocortical hormones API market is expected to hold a major global market share.. This is propelled by a growing number of dermatological disorders, such as eczema, psoriasis, and dermatitis, which require topical formulations of hydrocortisone, and the drug is essential in the treatment of adrenal insufficiency, which includes Addison’s disease and other similar disorders. More and more people are suffering from long-term health issues that necessitate the use of immunosuppressants and anti-inflammatory medications, which in turn drives the demand for hydrocortisone series. Growth in the prevalence of chronic health problems and an aging population suggests that the hydrocortisone series will be in high demand.
Injectable Drugs Segment To Witness Growth At A Rapid Rate.
Injectable drugs are growing because of their quick onset of action and precise control over dosage. These advantages make them ideal for adrenocortical hormone API treatments, which require exact concentrations for optimal efficacy. These advantages are especially important in acute care settings where therapeutic effects must be felt immediately. The expansion and improvement of healthcare infrastructure around the world, particularly the availability of medical facilities and healthcare workers trained to inject patients, is another factor fueling the evolution of this industry.
In The Region, The North American Adrenocortical Hormones API Market Holds A Significant Revenue Share.
The North American adrenocortical hormones API market is expected to record a largest market revenue share in the near future. This can be attributed to a well-established healthcare system that provides medical treatment to a large population and a high incidence of hormonal and endocrine diseases. In addition, Asia Pacific is estimated to grow rapidly in the global adrenocortical hormones API market because of a highly developed healthcare system, encourages the development of new pharmaceuticals, increases spending on healthcare, and a rising public and professional understanding of the significance of identifying and treating hormone abnormalities early in this region.
Recent Developments:
- In April 2021, Piramal Pharma Solutions (PPS) expressed its plan to purchase API manufacturer Hemmo Pharmaceuticals for a total of Rs 775 crore. Through this acquisition, PPS expanded its operations to include the development and production of peptide APIs. Hemmo was one of the few companies solely focused on manufacturing synthetic peptide APIs on a global scale.
Adrenocortical Hormones API Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.24 Bn |
|
Revenue Forecast In 2031 |
USD 3.55 Bn |
|
Growth Rate CAGR |
CAGR of 6.04% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, And End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Sanofi, GlaxoSmithKline, Xianju Pharma, Teva, Piramal Pharma Solutions, Guangzhou Tosun Pharmaceutical, BCN Peptides, Guangdong VTR Bio-Tech Co., Ltd, Symbiotec Pharmalab, Sun Pharmaceutical, Cipla, Hovione, Shandong Xinhua Pharmaceutical Company Limited, Steroid SpA, Junye Pharmaceutical Co., Ltd., Avik Pharmaceutical, Tianjin Pacific Pharmaceutical Co., Ltd (TJPP), Shandong Sito Bio-technology CO., LTD., and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
